Anita Brogan, PhD

Head, Decision Analytic Modeling, Health Economics

PhD, Operations Research
MSc, Operations Research
University of North Carolina, Chapel Hill, NC

BS, Mathematics
Harvey Mudd College, Claremont, CA

Anita Brogan, PhD, is Head of Decision Analytic Modeling at RT-HS. Dr. Brogan uses analytical techniques to assess and present the clinical and economic value of emerging pharmaceutical and biotechnology products. She has experience leading large health economics and market access projects in a variety of markets. She has also developed and presented various courses on decision-analysis modeling techniques, particularly in the area of budget-impact analysis. Dr. Brogan has led the development of cost-effectiveness, cost-utility, and cost-consequence models; budget-impact models; resource allocation models; infectious disease transmission models; and product value dossiers. She has experience with numerous types of modeling procedures, including Markov and other stochastic models, simulation, regression, linear and nonlinear programming, and various types of sensitivity analyses. She also has extensive experience programming models, user-friendly interfaces, and other software applications in Excel and other platforms. Dr. Brogan has developed models and analyses in the areas of HIV, hepatitis C, influenza, respiratory syncytial virus, pneumococcal disease, cystic fibrosis, women's health, diabetic nephropathy, colorectal cancer, breast cancer, non-Hodgkin's lymphoma, osteoporosis, chronic pain, age-related macular degeneration, schizophrenia, bipolar disorder, epilepsy, bone healing, hospital-acquired infection, financial portfolio optimization, and vehicle routing. Her research has been presented at professional conferences and published in peer-reviewed journals, including AIDS, American Journal of Health-System Pharmacy, American Journal of Preventative Medicine, Enfermedades Infecciosas y Microbiología Clínica, European Journal of Operational Research, HIV Clinical Trials, HIV Medicine, Human Vaccines & Immunotherapeutics, Pharmacoeconomics, and Value in Health.